Goldman Sachs Group Inc. Sells 4,449 Shares of Black Diamond Therapeutics, Inc. $BDTX

Goldman Sachs Group Inc. lessened its stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 0.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 479,387 shares of the company’s stock after selling 4,449 shares during the period. Goldman Sachs Group Inc.’s holdings in Black Diamond Therapeutics were worth $743,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. D. E. Shaw & Co. Inc. acquired a new position in shares of Black Diamond Therapeutics in the fourth quarter worth approximately $37,000. Invesco Ltd. raised its holdings in Black Diamond Therapeutics by 152.5% during the 1st quarter. Invesco Ltd. now owns 45,989 shares of the company’s stock worth $71,000 after purchasing an additional 27,777 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Black Diamond Therapeutics in the 1st quarter worth approximately $84,000. Brown Wealth Management LLC bought a new stake in shares of Black Diamond Therapeutics in the 1st quarter valued at $155,000. Finally, Bank of America Corp DE boosted its stake in shares of Black Diamond Therapeutics by 76.7% in the 4th quarter. Bank of America Corp DE now owns 74,719 shares of the company’s stock valued at $160,000 after purchasing an additional 32,422 shares during the last quarter. Institutional investors and hedge funds own 95.47% of the company’s stock.

Black Diamond Therapeutics Trading Down 7.3%

Shares of NASDAQ:BDTX opened at $3.17 on Wednesday. The stock has a market cap of $180.50 million, a PE ratio of 13.78 and a beta of 2.93. The stock’s fifty day simple moving average is $2.92 and its two-hundred day simple moving average is $2.29. Black Diamond Therapeutics, Inc. has a 1-year low of $1.20 and a 1-year high of $4.90.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its earnings results on Thursday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06. On average, sell-side analysts forecast that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BDTX has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Zacks Research raised Black Diamond Therapeutics to a “strong-buy” rating in a research report on Monday, August 11th. Guggenheim assumed coverage on Black Diamond Therapeutics in a research report on Wednesday, September 3rd. They set a “buy” rating and a $8.00 target price on the stock. HC Wainwright decreased their target price on Black Diamond Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Finally, Raymond James Financial raised Black Diamond Therapeutics to an “outperform” rating and set a $11.00 price target on the stock in a research note on Tuesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $11.00.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.